Alector Pharma launches Eklira Genuair
Date: 07 Oct 2015

Alector has launched a new chronic obstructive pulmonary disease (COPD) treatment, Eklira Genuair from AstraZeneca. Eklira Genuair is used as regular treatment for the relief of symptoms of COPD. The active substance in Eklira is aclidinium bromide, an anticholinergic bronchodilator. Genuair is a patient-friendly inhaler device.

For more information please click here.